Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Reviewing the Latest in Breast Cancer and Myeloma: Drs Tarantino and Raje

June 2nd 2024

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference

Revisit Every OncLive On Air Episode From May 2024

May 30th 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

Dr Landgren on the Utility of MRD as an End Point in Multiple Myeloma Trials

May 29th 2024

C. Ola Landgren, MD, PhD, discusses the utility of minimal residual disease as an end point in clinical trials for the treatment of multiple myeloma.

Dr Baljevic on the PERSEUS Trial in Untreated Multiple Myeloma

May 28th 2024

Muhamed Baljevic, MD, FACP, discusses the phase 3 PERSEUS trial in patients with previously untreated multiple myeloma.

Data for Quadruplet Therapies Could Alter Frontline SOC for Transplant-Ineligible Multiple Myeloma

May 28th 2024

Muhamed Baljevic, MD, FACP, discusses the investigation of frontline quadruplet therapies in transplant-ineligible multiple myeloma.

FDA Grants Priority Review to Isatuximab Combo for Newly Diagnosed, Transplant-Ineligible Myeloma

May 27th 2024

The FDA granted priority review to the sBLA for isatuximab plus bortezomib/lenalidomide/dexamethasone for newly diagnosed, transplant-ineligible myeloma.

First-Line Quadruplet Regimens Continue to Enhance Outcomes in Myeloma

May 25th 2024

Muhamed Baljevic, MD, FACP, discusses the evolution of quadruplet combination therapies in frontline multiple myeloma.

Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma

May 24th 2024

James Ignatz-Hoover, MD, PhD, discusses the evolving use of CAR T-cell therapies and bispecific antibodies in multiple myeloma.

Dr Baljevic on Key Considerations for Treatment Selection in Newly Diagnosed Multiple Myeloma

May 23rd 2024

Muhamed Baljevic, MD, discusses the consideration of patient comorbidities and preferences during treatment selection in newly diagnosed myeloma.

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

May 23rd 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Dr Jagannath on Safety Considerations With Ide-Cel in Multiple Myeloma

May 20th 2024

Sundar Jagannath, MBBS, discusses the FDA’s ODAC Meeting on safety considerations with ide-cel in multiple myeloma.

Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma

May 17th 2024

S. Vincent Rajkumar, MD, discusses highly anticipated abstracts in multiple myeloma that will be presented at the 2024 ASCO Annual Meeting.

Dr Baljevic on Advancements in the Management of Newly Diagnosed Multiple Myeloma

May 16th 2024

Muhamed Baljevic, MD, discusses key trial updates and advancements with quadruplet therapy in newly diagnosed multiple myeloma.

Dr Jagannath on the ODAC Meeting on the Safety of Cilta-Cel in R/R Multiple Myeloma

May 16th 2024

Sundar Jagannath, MBBS, discusses takeaways from the FDA’s ODAC consensus on safety considerations with cilta-cel in relapsed/refractory multiple myeloma.

Dr Jagannath on the Safety of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

May 14th 2024

Sundar Jagannath, MBBS, discusses the safety of linvoseltamab in relapsed/refractory multiple myeloma.

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024

In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.

Dr Ignatz-Hoover on Sequencing CAR T-Cell Therapy and Bispecific Antibodies in R/R Myeloma

May 14th 2024

James Ignatz-Hoover, MD, PhD discusses sequencing CAR T cell therapies and bispecific agents in treating pretreated patients with multiple myeloma.

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.

The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma

May 13th 2024

Following the consensus that the risk-benefit assessments for the proposed indications for cilta-cel and ide-cel were favorable during the March 15, 2024, FDA ODAC meeting, both BCMA-targeted CAR T-cell therapies received approvals moving them up in the treatment paradigm for relapsed or refractory multiple myeloma.

Dr Jagannath on the Safety Considerations With CAR T-Cell Therapy Multiple Myeloma

May 10th 2024

Sundar Jagannath, MBBS, discusses CAR T-cell therapy considerations prior to initiation in the management of multiple myeloma.